Please visit answersincme.com/EYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses approved and emerging TROP2-directed ADCs for the treatment of HR-positive, HER2-negative/low advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for using TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced breast cancer; Discuss the clinical impact of approved and late-stage emerging TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer; and Outline guideline-concordant, evidence-based strategies to appropriately incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related